Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464606 · ClinicalTrials.gov registry record · NA
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry
A NA study of Pleuropulmonary Blastoma, sponsored by Children's Hospitals and Clinics of Minnesota.
- Active
- Registry status
- NA
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT01464606: Active NA study of Pleuropulmonary Blastoma, sponsored by Children's Hospitals and Clinics of Minnesota.
NCT01464606 is a NA study of Pleuropulmonary Blastoma that is active but no longer recruiting, run by Children's Hospitals and Clinics of Minnesota. The registered enrollment target is 156 participants, below the 1,670-participant average among 3 other Pleuropulmonary Blastoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01464606, a NA study of Pleuropulmonary Blastoma, is active but no longer recruiting, sponsored by Children's Hospitals and Clinics of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
Pleuropulmonary Blastoma (PPB) is very rare and there is no established "standard" or "best" therapy. For many years, children with PPB around the world have been treated according to decisions made case-by-case in many different hospitals by many different physicians. No treatment has been tested in a large group of PPB patients. The goal is to treat many children with one treatment program and to learn the results of the treatment.
Primary Outcome
The primary endpoint for statistical analysis will be time from start treatment to an event, defined as the occurrence of progression or recurrence of PPB, occurrence of a second malignant neoplasm, or death from any cause that is at least possibly related to the original disease or treatment.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Ifosfamide
- DRUG Dactinomycin
Study Locations (1)
Minnesota
- Anne K Harris - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2009-12-22 |
| Est. Completion | 2028-12 |
| Phase | NA |
What the registry record for NCT01464606 still lists
NCT01464606 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 1,670-participant average among 3 other Pleuropulmonary Blastoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Pleuropulmonary Blastoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01464606 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01464606 about?
NCT01464606 is a clinical study titled "International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry". Pleuropulmonary Blastoma (PPB) is very rare and there is no established "standard" or "best" therapy. For many years, children with PPB around the world have been treated according to decisions made case-by-case in many different hospitals by many different physicians. No treatment has been tested i...
What is the current status of trial NCT01464606?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 156 participants. The study started on 2009-12-22. Estimated completion is 2028-12.
What conditions does trial NCT01464606 study?
This clinical trial studies the following conditions: Pleuropulmonary Blastoma.
What interventions are being tested in trial NCT01464606?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Ifosfamide (DRUG), Dactinomycin (DRUG).
Who is sponsoring clinical trial NCT01464606?
This trial is sponsored by Children's Hospitals and Clinics of Minnesota, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01464606 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleuropulmonary Blastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
International PPB/DICER1 Registry
RECRUITING
-
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
RECRUITING · Phase 3
-
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI